Neural Systems Division

Brain-Computer Interfaces &
Neuroprosthetic Restoration

Closed-loop neural technologies translating cortical intent into motion, communication, and sensory restoration for clinical and consumer applications.

147 Active Patents
Phase III Leading Clinical Trial
98.4% Signal Fidelity Rate
12 Clinical Sites

Bridging Neural Intent and Physical Action

Aevum Zenth Neural Systems (AZNS) develops implantable and non-invasive brain-computer interfaces, paired with adaptive neuroprosthetic actuators and AI-driven decoding engines. Our architecture operates on a closed-loop feedback paradigm: capturing high-fidelity neural spikes, processing intent via edge-AI inference, and delivering tactile/proprioceptive feedback to restore motor function, communication pathways, and sensory perception.

Platform Architecture

🧠

Cortical Micro-Interface (CMI-9)

Fully implantable, flexible polymer electrode array with 1024 independent channels. Biocompatible encapsulation reduces glial scarring by 74% over 24-month trials.

1024 Channels Ultra-Low Power Wireless Power
🦾

Proprioceptive Feedback Actuators

Neuroprosthetic limbs with embedded micro-sensors delivering closed-loop tactile and kinesthetic feedback directly to somatosensory cortex pathways.

12-DOF Haptic Return Modular

NeuralDecode AI v4

Edge-optimized transformer model running locally on implant hardware. Real-time spike sorting, artifact rejection, and intent prediction at <12ms latency.

<12ms Latency On-Device AI Self-Calibrating
📡

Hybrid EEG/MEG Clinical Array

Non-invasive wearable headset for research, rehabilitation, and consumer BCI applications. Enterprise SDK available for clinical research partners.

Non-Invasive 64-Channel API Ready

Development Milestones

Q2 2023
CMI-9 Preclinical Validation
Completed chronic implantation studies in primate models. Demonstrated stable recording fidelity over 18 months with minimal tissue response.
Q1 2024
FDA Breakthrough Device Designation
Granted for motor restoration in spinal cord injury and ALS patient cohorts. Fast-tracked clinical trial pathway initiated.
Q3 2025 - Q4 2026
Phase III Clinical Trials (AZNS-01)
Multi-center trial across 12 sites. Evaluating motor restoration, communication interfaces, and closed-loop prosthetic control in 480 subjects.
H2 2027
Commercial Deployment & Insurance Coverage
Targeted FDA approval and global CE marking. Integration with major healthcare providers and neurological rehabilitation networks.
Active Clinical Sites 12
Enrolled Subjects (Phase III) 312 / 480
Motor Function Restoration (Avg) +84% FIM Score
Adverse Events (Severe) 0.04%
Publications (2024-2025) 47 Peer-Reviewed

Neuro-Ethics & Regulatory Compliance

Neural technology demands unprecedented responsibility. AZNS operates under a strict neuro-rights framework, ensuring patient autonomy, cognitive liberty, and mental privacy. All systems are designed with hardware-level encryption, local-only data processing, and explicit user consent protocols.

🔒

Cognitive Liberty

Users retain full control over data streams. Neural data is never sold, shared, or processed without explicit, revocable consent.

🛡️

FDA & CE Mark Compliant

Full adherence to ISO 13485, FDA QSR 820, and EU MDR regulations. Independent IRB oversight for all clinical protocols.

⚖️

Algorithmic Transparency

Open audit trails for NeuralDecode AI. Third-party validation ensures bias mitigation and clinical reliability across demographics.

🌐

Hardware-Level Encryption

AES-256 encryption on all neural telemetry. Zero-knowledge architecture ensures implants cannot be remotely accessed or modified.

Academic & Clinical Collaborations

Co-developing the next generation of neural interfaces with leading institutions worldwide.

MIT Brain & Cognitive Sciences
Karolinska Institute
NIH BRAIN Initiative
Stanford NeuroBioLab
University of Tokyo Neurosurgery
Mayo Clinic Neurological Dept
ETH Zurich Neuroengineering
Imperial College London

Partner with AZNS

Whether you're a clinical researcher, healthcare provider, or institutional investor, explore how our neural platforms are redefining human-machine integration.